Share on

Global Prostate Cancer Market Size, Share, Growth, Trends, COVID-19 Impact & Analysis Report – Segmented By Diagnostic Techniques (Digital Rectal Exam (DRE) and Prostate-Specific Antigen Test (PSA)), Chemotherapy and Region - Industry Forecast (2022 to 2027).

Published: January, 2022
ID: 1536
Pages: 175
Formats: report pdf report excel report power bi report ppt

Global Prostate Cancer Market Size (2022 to 2027)

As per our report, the global prostate cancer market is projected to be worth USD 99.20 billion by 2027 and USD 63.02 billion in 2022, growing at a CAGR of 9.5% during the forecast period.

Some of the key findings of the report:

  • Based on the diagnostic techniques, the PSA test segment dominated the market in 2021.
  • Based on the surgery, the radical prostatectomy segment had the leading share of the market in 2021.
  • Based on radiation therapy, the external-beam radiation therapy segment held a significant share of the prostate cancer market in 2021.
  • The North American region led the market and was valued at USD 19.69 billion in 2021.
  • The market size in the European region is expected to grow to USD 28.72 billion by 2027.
  • The market in the Asia-Pacific region is anticipated to rise at a CAGR of 11.49% from 2022 to 2027.

The treatment market for prostate cancer has a high demand for novel drugs that concentrate on unmet needs, such as improved survival time, less toxicity, better progression-free survival, improved effectiveness, and lesser cost. Prostate cancer is a prostate cancer progression, a gland present in the male reproductive system. The cancer cells might reach the other parts of the body, viz., the bones and lymph nodes from the prostate. In the later stages of cancer, it can cause urination, blood in the urine, etc. Prostate cancer is most of the time diagnosed by biopsy.

Impact of COVID-19 on the global prostate cancer market:

The coronavirus (COVID-19) pandemic has disrupted the world and has affected almost every sector in every corner. The crisis has added an excess layer of pressure or burden on many people. Treating patients efficiently during the pandemic crisis has become a significant challenge for clinicians. Prostate cancer patients are at mounting risk of coronavirus infection and illness and death if infected. Prostate cancer services are on hold due to the changing medical and surgical importance. Once accurately organized and to reduce the spread of the virus, prostate cancer patients can observe telemedicine, establish lifestyle changes, and maintain social distancing. Prostate cancer patients need to be followed up remotely unless and until the COVID-19 pandemic sets right. Prostate cancer patients have amplified occurrences and mortality from COVID-19 infection due to gender, age, and propensity factors.

MARKET DRIVERS:

YOY growth in the prevalence of prostate cancer, increasing public awareness of prostate cancer therapy, greater R&D investment by drug developers, strong upcoming pipeline medicines, and the availability of novel prostate cancer treatments are majorly propelling the prostate cancer market.

Although the specific cause of prostate cancer is unknown, being overweight, obese, and having any other tumorous development history are all risk factors. Even people with cardiovascular problems are susceptible to cancer metastases. As a result, all these are the factors driving the market expansion. In the male population, prostate cancer is the second most prevalent cancer. Prostate cancer is more frequent in the senior population, and the world's population is expected to age, driving the market growth. Altering lifestyles, technological advancements in researching new techniques to fight prostate cancer, and increased funding in public and private sectors in drug advancement are some key reasons driving the global prostate cancer market growth.

The prostate cancer market is further expected to be fuelled by using innovative technologies in screening and diagnostic testing.

For instance, Multiparametric MRI (MP-MRI) can significantly enhance tumor identification while confirming whether tissue biopsy is required. In addition, due to several generic goods anticipated to join the market of the expiry of patents on vital current products throughout the forecast period, Seva's result growth is expected to be fuelled by these factors. Other factors that contribute to the market's growth include an increase in demand for prostate cancer therapy and care and an increase in the use of hormonal drugs in non-metastatic castration-resistant and metastatic hormone-naive prostate cancer situations. The developing nations' untapped potential offers attractive opportunities for market expansion.

Furthermore, the prostate cancer market is further anticipated to expand during the forecast period due to growth opportunities such as untapped market potential due to unmet medical treatment requirements, growing awareness among people, and advancements in the healthcare field. Further, the patent expiration of significant drugs like Zytiga will likely provide lucrative opportunities during the forecast period.

MARKET RESTRAINTS:

Ever-changing reimbursement policies, extending the time span of treatment, the expensive nature of combination therapies, and managing the life cycle of drugs are hampering the prostate cancer market growth.

In addition, the shortage of skilled people to monitor the equipment in laboratories is slowly degrading the growth of the prostate cancer market. Besides, government bodies' frequent changes in economic strategies are hindering the market's growth rate. The market's growth is projected to be restricted by extended treatment times and low demand for prostate cancer medicines in developing nations. The market is also likely limited by the high cost of prostate cancer medicines and the low success rate of clinical trials. In addition, the high expenses of a tissue biopsy, especially during the advanced stages of a tumor, and medical consultation fees, are predicted to limit growth. Furthermore, issues such as inadequate reimbursement of treatment expenses may hurt the adoption rate of treatment techniques.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2021 to 2027

Base Year

2021

Forecast Period

2022 to 2027

Segments Covered

By Diagnostic Techniques, Surgery, Radiation Therapy, Chemotherapy, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

This research report on the global prostate cancer market has been segmented and sub-segmented based on diagnostic techniques, surgery, radiation therapy, chemotherapy, and region.

Prostate Cancer Market – By Diagnostic Techniques:

  • Digital Rectal Exam (DRE)
  • Prostate-Specific Antigen Test (PSA)

Based on the diagnostic techniques, the prostate-specific antigen test (PSA) segment is expected to grow at a healthy CAGR during the forecast period. The PSA test is to diminish the possibility of death from cancer. The amplifying research and development activities are accompanying the booming ubiquity of castrate-resistant prostate cancer. The factors mentioned above foster market growth.

Prostate cancer is one of the most common cancers diagnosed among men aged over 45 years. The success rate of the treatment regimen is increased by timely screening and early diagnosis using PSA and DRE. The governments of industrialized nations are organizing and executing initiatives to raise awareness of screening tests for male patients over 50 years old, such as Prostate-Specific Antigen blood tests and Digital Rectal Exams (DRE). Prostate Cancer Canada was founded to assist in the research, treatment, and prevention of prostate cancer.

Prostate Cancer Market – By Surgery:

  • Radical Prostatectomy
  • Orchidectomy
  • Trans Urethral Resection (TUR)

A radical prostatectomy is the most common kind of prostate cancer surgery. During this operation, the surgeon removes the whole prostate gland and some surrounding tissue, including the seminal vesicles. The prostate gland and surrounding tissues are removed during radical prostatectomy. As a result, the seminal vesicles and several surrounding lymph nodes are frequently included. Prostate cancer localized to the prostate can be cured by radical prostatectomy.

Prostate Cancer Market – By Radiation Therapy:

  • External Beam Radiation Therapy
    • 3D Conformal Radiation Therapy
    • Intensity Modulated Radiation Therapy
    • Stereotactic Body Radiation Therapy
    • Proton Beam Radiation Therapy
  • Brachytherapy
    • Permanent Brachytherapy
    • Temporary Brachytherapy

Based on radiation therapy, the most frequent kind of radiation treatment is external-beam radiation therapy. The radiation oncologist uses equipment outside the body to focus a beam of x-rays on the cancer area. For instance, radiation therapy for prostate cancer includes destroying tumors with high-energy beams or radioactive seeds. Brachytherapy, Intensity Modulated Radiation Therapy (IMRT), stereotactic radiosurgery, and proton therapy are the most frequent treatments for prostate cancer.

Prostate Cancer Market – By Chemotherapy:

  • Docetaxel
  • Etoposide
  • Vinblastine
  • Carboplatin
  • Vinorelbine

Based on the chemotherapy, Docetaxel, the most frequent chemotherapy treatment for prostate cancer, is commonly used with prednisone, a steroid medication. Many men report improvements in disease-related symptoms such as pain, fatigue, and energy loss after starting docetaxel.

Prostate Cancer Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Regionally, the North American prostate cancer market has contributed a prominent share in recent years and is expected to grow exponentially during the forecast period. As a result, North America dominated the worldwide market in 2021, accounting for the highest share in the global market. The primary causes for North America's market domination are the rising prevalence and high death rate of prostate cancer in the United States. In addition, this region is seeing a lot of money invested in R&D to create novel immunotherapy and targeted pharmacological treatments to treat these cancers.

The Asia Pacific prostate cancer market is growing at the fastest CAGR in the global market due to factors such as increasing economies of the developing nations, rising youth population, rising prostate cancer cases in older people, and increasing focus on promoting preventive drugs and research initiatives. In addition, due to rising awareness of prostate cancer treatment and acceptance of prostate cancer treatment products, Asia-Pacific provides attractive opportunities for significant prostate cancer treatment market players. Furthermore, advances in healthcare infrastructure, an increase in the number of hospitals with sophisticated medical facilities, a growing R&D sector, increased healthcare reforms, and technical advancements in healthcare all contribute to market growth.

The European prostate cancer market accounted for a substantial share of the global market in 2021.

The prostate cancer market in the Latin American region is estimated to record a healthy CAGR during the forecast period.

The MEA prostate cancer market is anticipated to grow at a moderate CAGR from 2022 to 2027.

KEY MARKET PARTICIPANTS:

Prominent companies dominating the global prostate cancer market profiled in the report are Sanofi S.A., GlaxoSmithKline, AstraZeneca, AbbVie, Varian Medical Systems, Elekta, Theragenics, Pfizer, Novartis, Roche, Bayer, Johnson & Johnson, Abbott Laboratories, and Genentech.

RECENT MARKET DEVELOPMENTS:

  • Pfizer Company completed the Array Biopharma acquisition in June 2019; Pfizer is looking forward to expanding its product portfolio and research operations regarding prostate cancer with the biotech giant Array Biopharma.
  • In September 2019, The National Institute of Health revealed that prostate cancer screens might turn to biomarkers in semen. Therefore, the edible and hub have collaborated to research extracellular miRNAs. As the research outcomes, they concluded that semen exosome miRNA-based biomarkers could improve the diagnosis of prostate cancer. 
  • Johnson and Johnson's company has developed a drug called Erleada for treating metastatic hormone-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer, which has got approved by the FDA in February 2018.
  • A company based in the U.K launched a new advanced ultrasound imaging technique in 2018; the technique is integrated with artificial intelligence to enhance prostate cancer detection.
  • Mayroy SA Company demerged from Ispen Company in December 2019. 
  • In 2019, Profound Medical Inc. developed a TULSA tool (MRI-guided transurethral ultrasound ablation) for treating prostate cancer and enlarged prostate at high accuracy without any side effects.
  • Prostate cancer can be diagnosed accurately, more shortly, and simply by conducting urine tests at home, and the Pilot Study confirmed this was conducted very recently.

Please wait. . . . Your request is being processed

FAQ's

How big is the global prostate cancer market size?

The global prostate cancer market size is expected to grow by USD 99.2 billion by 2027 and was valued at USD 63.02 billion in 2022.

Does this report include the impact of COVID-19 on the prostate cancer market?

Yes, we have studied and included the COVID-19 impact on the global prostate cancer market in this report.

Which region led the prostate cancer market in 2021?

In 2021, the North American region occupied the majority of the share in the global prostate cancer market.

Which are the major players operating in the prostate cancer market?

Sanofi S.A., GlaxoSmithKline, AstraZeneca, AbbVie, Varian Medical Systems, Elekta, Theragenics, Pfizer, Novartis, Roche, Bayer, Johnson & Johnson, Abbott Laboratories, and Genentech are some of the noteworthy companies operating in the global prostate cancer market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: sales@marketdataforecast.com

Click for Request Sample